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Abstract
The nicotinamide riboside (NR) form of vitamin B3 and the ketone body ß-hydroxybutyrate
(BHB) are two of the most promising natural compounds yet identified for the treatment of aging
and aging-related diseases. Forms of vitamin B3 are precursors for the synthesis of the
coenzymes nicotinamide adenine dinucleotide (NAD(H)) and nicotinamide adenine dinucleotide
phosphate (NADP(H)). In aged cells levels of NAD+ decline, decreasing metabolism and
decreasing activity of protective sirtuin protein deacetylases. In aged cells NR, but not more
common forms of vitamin B3, boost NAD+ levels. BHB is naturally produced by the body when
individuals fast or consume a ketogenic (KD) or calorically restricted (CR) diet. These diets have
been shown to extend lifespan in mice, while they are also protective in many disease models.
Caenorhabditis elegans, a roundworm with a short mean lifespan of roughly 2 to 3 weeks
depending upon the temperature, is used as a model system to study aging. BHB has been
previously shown to increase lifespan by roughly 20% when administered to C. elegans. We
administered NR and BHB individually and together to C. elegans starting at two different
developmental stages (larval stages 1 and 4) and measured lifespan. We found that
administration of 20 mM DL-BHB decreased lifespan when first given at the L1 stage, while it
robustly increased lifespan when first given at the L4 stage. Administration of 0.5 mM NR
increased lifespan when first given at L1, with only a very slight increase when first given at L4.
When initiating administration at L1, NR greatly mitigated the BHB-mediated decline in
longevity, however, NR did not increase BHB-mediated lifespan extension when first
administered at L4.
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Introduction
Nicotinamide adenine dinucleotide (NAD+) is an important coenzyme that is used in
hundreds of enzymatic reactions and almost all major metabolic pathways [1]. Levels of NAD+
decline with human aging, and this appears to contribute to mitochondrial dysfunction and other
metabolic decline in age-related diseases [2-6]. It has also been shown that NAD+ levels decrease
with age in mice and the nematode Caenorhabditis elegans. Genetically decreasing NAD+ levels
also decreases lifespan [7]. Therefore, increasing cellular levels of NAD+ has been hypothesized
to increase lifespan in mammals. This hypothesis was tested in C. elegans and as expected, the
increased NAD+ levels upregulated sirtuin protein activity, decreased metabolic decline, and
increased lifespan [7].
Nicotinamide riboside (NR) is a form of vitamin B3 that was first shown in yeast to be a
precursor to NAD+ [8]. Not long after, administration of NR to yeast cells was shown to increase
lifespan [9]. More recently, a large number of NAD+ precursor feeding studies were performed
in rodents that showed that increasing NAD+ levels had “a favorable outcome” on a number of
age-related disorders characterized by “chronic oxidative stress, inflammation, and impaired
mitochondrial function” [10]. It is likely that NR treatment increases nucleo-cytoplasmic and
mitochondrial NAD+ levels and the activity of sirtuin proteins, which leads to increased lifespan.
In summary, these data show that NR has great potential for the treatment of age-related diseases
in humans.
The oldest known method of lifespan extension is the calorie restriction diet (CR). CR
was first shown to increase lifespan in rats over 80 years ago [11]. It is hypothesized that CR
extends lifespan by slowing and/or delaying the process of aging. It has been shown in mice that
CR causes a shift from glucose to fatty acid and ketone body metabolism, because on this diet
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carbohydrates are present at too low of levels to supply all of the energy the body needs [12].
However, neurons are unable to readily oxidize fatty acids, but can instead oxidize ketone bodies
when glucose levels are low. Recently, scientists became interested in the effects on longevity of
a ketogenic diet (KD), where the main source of energy is obtained through a high fat, low
carbohydrate diet. During ketosis, the body, especially neurons, does not have enough
carbohydrates to supply energy needs, and so fatty acids are broken down into the ketone bodies
acetone, acetoacetate, and ß-hydroxybutyrate (BHB) in the liver and then distributed to
peripheral tissues in the circulation, which fill this energetic need. BHB has both D- and Lisomers, with the D- form being the one produced in the body under carbohydrate depleted
conditions.
Studies were performed in order to determine if KD or other diets that increase ketone
body levels could induce anti-aging effects similar to those induced by the CR diet. Studies using
either C. elegans or mice showed that increasing BHB levels increased lifespan in a similar way
as that occurs when signaling through the insulin/insulin-like growth factor receptor is decreased
[13]. Another study found that KD further helped to preserve “motor function, memory, and
muscle mass in aged mice”, further showing that KD can be a successful way to increase lifespan
and improve health over the lifespan of animals undergoing this diet [14]. Another study showed
that a cyclic KD (where high carbohydrate, high fat, and ketogenic diet cycles were alternated
each week from 12-24 months of age) in mice showed a reduction in mid-life mortality rates and
preserved memory function [15].
With KD being shown to increase lifespan, the effects on lifespan of individual ketone
bodies that are increased by the KD were also studied. The most abundant and most stable
ketone body is BHB, and as such most research has focused on it. In fact, one study showed that
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treatment of C. elegans with D-BHB increased lifespan by an average of 20% [16]. One pathway
by which BHB was shown to extend lifespan was by inhibiting histone deacetylases (HDACs).
BHB was shown to increase histone acetylation leading to upregulation of the expression of the
FOXO3a transcriptional regulator in mammals and likely the homologous daf-16 gene in C.
elegans. Another proposed protective pathway is the stimulation of mitochondrial metabolism,
where increased BHB levels increase mitochondrial metabolism of BHB, causing increased citric
acid cycle (CAC) intermediates (which lead to activation of DAF-16/FOXO). BHB-mediated
lifespan extension was also shown to require activation of the Nrf2 (SKN-1 in C. elegans)
transcriptional regulator, which can be activated by increased reactive oxygen species (ROS)
produced from increased mitochondrial metabolism. SKN-1/Nrf-2 increases antioxidant gene
expression [17]. These proposed pathways overlap and are shown in Figure 1. The study using C.
elegans indicated that D-BHB does indeed extend lifespan through the HDAC inhibition
pathway, as well as through “conserved stress response pathways” such as the DAF-16/FOXO
and SKN-1/Nrf-2 antioxidant pathways described above [16].
The mechanisms through which increased activities of the DAF-16/FOXO and SKN1/Nrf2 transcriptional regulators extend lifespan are not completely known, as each regulates the
expression of hundreds of genes. But since these factors increase the resistance to multiple
stresses (oxidative stress, thermal stress, unfolded protein stress, starvation, etc. ) they are master
regulators capable of fine tuning many cellular functions to improve metabolism, antioxidant
defense, and protein synthesis, stability, and turnover. The genes and proteins they encode likely
evolved these functions for organisms to delay reproduction during times of stress as egg-laying
is frequently delayed when these transcriptional regulators are activated. The lifespan extension
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that occurs may therefore be a byproduct of the increased stress resistance mechanisms
established to be able to delay reproduction.

Figure 1: Possible Pathways Mediating Lifespan Extension via BHB Treatment in C. elegans.

Part of the rationale behind performing this research was to determine if NR and BHB
have an additive effect on lifespan, which would occur if they function through independent
pathways, or alternatively if they activate a shared metabolic pathway that would prevent an
additive effect. C. elegans serves as a good model for such an experiment. These roundworms
are small, roughly about 1 mm in size, and have four larval stages. If kept at room temperature
for three days, they reach their gravid stage of development, being able to lay eggs at that time
[18]. They are also useful in the study of human aging and aging-related disease, as 40% of
human disease genes have a homolog present in the C. elegans genome [19]. They also have an
average lifespan of 2-3 weeks, making their use more time-efficient than using longer-lived
mammalian organisms [20].
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Because of these benefits, C. elegans serves as an efficient model to quickly perform
lifespan assays and to gather data in a relatively small amount of time. While NR and BHB are
both compounds of interest in the fields of longevity research, their effects on lifespan when
added together remain unknown. It is hypothesized that NR and BHB will confer an additive
effect on lifespan in C. elegans, working on independent metabolic pathways to increase lifespan
further than either compound would when added individually. There is also interest regarding
whether the lifespan-extending effects of these compounds occur during the developmental
stages as this is the case for some long-lived mitochondrial mutant strains or strictly during
adulthood. Therefore, treatment was first initiated at either the first larval stage (L1) or the final
larval stage (L4).
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Materials and Methods
Cultures of mixed age wild-type N2 strain C. elegans nematodes were grown on
nematode growth media (NGM) agar plates and washed from the agar into 50 mL conical tubes
using a 0.1 M NaCl solution. Worms were then suspended in a 1% bleach and 0.5 M NaOH
solution to kill the larvae and adult C. elegans, leaving only eggs that were protected by their
thick eggshell. The eggs obtained are age-synchronized to within 9 hours, in order to have a
same-age population for lifespan assays. Eggs were then placed in M9 minimal growth media
overnight, when worms will hatch into larval L1 stage. C. elegans will stay overnight in this
stage, as they will not develop further until fed [18]. Worms in the larval L1 stage were then
transferred into 8-micron cell culture inserts placed in 12-well microplates with roughly 25-60
eggs per insert. The inserts provide a semi-permeable membrane that allow food (bacteria) and
waste products to move through the membrane while keeping C. elegans from escaping. 1.35 mL
of liquid S-media was added to the outer portion of each of the 12 well plates, followed by 0.15
mL 9 x109 (10 mg protein/mL) HT115(DE3) empty vector E. coli cells/mL which served as
food. C. elegans were given live bacteria up until day 3 of each experiment, to allow for proper
nutrition during their developmental stages, after which worms were exclusively fed only heatkilled bacteria (of the same concentration and strain) to prevent the bacteria from metabolizing
the treatment compounds. In total, this caused the final volume of each well to equal roughly 1.5
mL. Microplates were incubated at 20˚C and shaken at 60 rpm to provide aeration throughout the
duration of the experiment. After 3 days, worms reached adulthood and 0.4 mM
fluorodeoxyuridine (FUdR), a DNA synthesis inhibitor, was added to each of the 12 well plates.
This prevented C. elegans from laying eggs, which maintained the synchronous population. The
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worms were counted under a microscope and the culture media, FUdR, and bacteria were
replaced every Monday, Wednesday, and Friday for the entirety of each assay.
On these same days, some cohorts of worms (excluding the control groups) were also
treated with either a 20 mM 50:50 mixture of D- and L-BHB, 0.5 mM nicotinamide riboside, or
both. The only difference between the two experiments performed was whether C. elegans were
first treated with NR, BHB, or both on day 1 of the experiment (when C. elegans were at the L1
stage of development) or day 3 of the experiment (when C. elegans were at the L4 stage). Upon
death of the entire population of C. elegans for each well of the 12-well plate, the percent
survival over time for each trial was averaged and the mean lifespans over time were calculated
using Kaplan-Meier survival curves and Log-rank statistical analysis. In total, 3 independent
trials were performed for both conditions, initiating treatment at either the L1 or L4 stage of
development in C. elegans. The data collected is displayed in the Results and Discussion section
below.
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Results and Discussion
The effects of BHB or NR on C. elegans mean lifespan when added alone or together
starting at either the L1 (Table 1) or L4 (Table 2) larval stages is summarized in Table 3. Overall,
the data show that 0.5 mM NR increases mean lifespan greatly when first given at L1, but only
very slightly when initiated at L4, while 20 mM DL-BHB greatly decreased mean lifespan when
first given at L1, but greatly increased mean lifespan when first given at L4. When NR was
added to BHB starting at L1, it blocked the detrimental effects of BHB on lifespan by 45%, but
when NR was added with BHB starting at L4, it had no statistically significant effect on the large
BHB-mediated mean lifespan extension.
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Figure 2: Survival analysis when NR, BHB, or both were first administered at L1
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Figure 3: Survival analysis when NR, BHB, or both were first administered at L4

Table 1: Mean lifespan when treatment was initiated at L1
Treatment
Mean Survival Time
Control
18.384
NR
21.992
BHB
10.962
NR+BHB
14.381
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Table 2: Mean lifespan when treatment was initiated at L4
Treatment
Mean Survival Time
Control
17.854
NR
18.433
BHB
21.584
NR+BHB
20.977

Table 3. Percent change in mean lifespan when NR, BHB, or both were administered
Treatment
L1 First Treatment
L4 First Treatment
NR
+20%
+3%
BHB
-40%
+21%
NR+BHB
-22%
+18%

Our data indicate that NR is almost exclusively extending lifespan by acting during the
larval stages and BHB is exclusively shortening lifespan during this time as well. BHB appears
to be extending lifespan exclusively during adulthood. Therefore, it also appears that NR and
BHB are functioning through independent pathways. The ability of NR to greatly extend (by
31%) the BHB-shortened lifespan when both compounds were first administered at L1 further
supports this conclusion. A further lifespan experiment showing additive effects where NR is
administered starting at L1 and BHB is administered starting at L4 would strengthen this
hypothesis.
The ability of BHB to exclusively extend lifespan during adulthood is consistent with a
mechanism of lifespan extension through the activation of the DAF-16/FOXO and SKN-1/Nrf2
transcriptional regulators that function during adulthood to extend lifespan [21-22]. The ability
of NR to extend lifespan almost exclusively during the larval stages is consistent with its
activation of the mitochondrial unfolded protein response (UPRmt) [7], which functions
exclusively during the larval stages to extend lifespan [23]. The ability of 0.5 mM NR to extend
lifespan was blocked by knockdown of ubl-5, a mediator of UPRmt [7]. However, 0.5 mM NR-
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mediated lifespan extension was also blocked in daf-16 mutant worms. This suggests that
activation of DAF-16/FOXO is shared by both BHB and NR treatments.
How does BHB decrease lifespan when administered during the larval developmental
stages? It is likely that the ability of BHB to function as an HDAC inhibitor mediates this
function. BHB functions as a class I HDAC inhibitor [24]. C. elegans has three class I HDAC
genes: hda-1, hda-2, and hda-3. Partial knockdown of hda-2 or hda-3 increased lifespan and
prevented BHB from further extending lifespan, while full knockout of hda-2 or hda-3 decreased
lifespan [16]. This data, together with the ability of a lower 10 mM dose of BHB than the 20 mM
dose used here, to extend C. elegans lifespan when administered starting at L1, suggests that
when BHB only partially inhibits HDAC function during development, lifespan can be increased
by HDAC inhibition during adulthood. But when BHB completely inhibits HDAC function
during development, lifespan is decreased and cannot be increased by HDAC inhibition during
adulthood.
To support the conclusions drawn from our data, further experiments could be performed
where NR, BHB, or NR+BHB are added only from the L1 through L4 larval stages and not
during adulthood. It is hypothesized that nearly the same results on lifespan would occur as those
found here when adding the compounds from L1 until the end of the lifespan. Experiments could
also be performed where these compounds are only administered from mid-adulthood onward.
The results of such experiments would better model the effects of these compounds when taken
by middle-aged humans. NR and BHB have different temporal requirements for lifespan
extension in C. elegans, with NR functioning almost exclusively during development and BHB
functioning almost exclusively during adulthood. BHB, at the high concentration administered
here, was toxic to larval C. elegans. The concentration of BHB administered here (20 mM) is
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roughly equal to the levels in human patients with very severe ketoacidosis, but the level inside
the worms is likely 10-fold lower, roughly the level occurring in humans after a 24-hour fast
[24].
Further NR supplementation experiments could be performed to determine the optimal
time frame for NR treatment to increase the lifespan, while preventing wasteful treatment during
times it does not affect lifespan. These experiments could start by treatment of NR only during
the developmental stages and then transition into further treatment during early adulthood.
To better understand the best time to initiate BHB supplementation in order to optimize
lifespan extension, further experiments could be performed initiating BHB administration at the
L2 or L3 larval stages. Lifespan experiments could also be performed using an RNAihypersensitive worm strain to determine if a more complete knockdown of the hda-2 or hda-3
HDACs from the L1 larval stage decreases lifespan, as this treatment increased lifespan in the
normal N2 worm strain. If lifespan is decreased by knockdown in the RNAi-hypersensitive
strain, RNAi treatment could be initiated at the L2, L3, or L4 larval stages using this strain to
determine the larval stage in which HDAC inhibition is toxic. This would allow a temporal
understanding of the effects of HDAC inhibition during the larval stages on lifespan, which
would likely suggest the optimal time to initiate BHB supplementation in order to maximize
lifespan.
Due to the toxic effects of 20 mM BHB administration during larval development and the
apparent requirement of NR administration during larval development for lifespan extension, the
experiments performed here were not able to directly address our major research hypothesis that
BHB and NR have additive effects on lifespan extension. To directly address this hypothesis our
data suggest that NR treatment should be initiated at L1 and continue until at least L4, after
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which NR treatment will likely have minimal effect on lifespan. Our data also suggest that L4 is
the developmental stage where 20 mM DL-BHB administration should be initiated and treatment
should be continued throughout the rest of the lifespan for maximal extension of lifespan.
The future experiments described above were designed to find the temporal “sweet
spot” where combined NR and BHB addition maximize longevity. Positive results in these
experiments would support the hypothesis that these compounds have additive effects when
added at the optimal times, while also identifying the maximal lifespan extension provided by
these two compounds. Optimization of the concentrations and temporal requirements of these
compounds will allow for the future testing of multi-compound cocktails, which function by
multiple mechanisms to augment lifespan in C. elegans, and eventually be tested in mammals,
including human clinical trials.
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Conclusions
Overall, the data suggests the ability of NR and BHB addition during different stages of
life to enhance lifespan, which could also likely lead to the delay of age-related diseases. The
research also demonstrates how a compound can have drastically different effects on lifespan
depending upon the developmental stage at which it is first applied. As such, published results
should always explicitly indicate the life stage that treatments are first applied. Now that the
temporal requirements of these compounds for maximizing longevity have been identified, these
compounds can be added together with other novel longevity interventions and administered to
C. elegans to identify potent anti-aging cocktails. This can be accomplished with minimal cost
and time. These experiments could yield profound results that can be scaled up for the treatment
of many human aging-associated diseases.
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